Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-12-22

Clinical Trial Update: S0635: Erlotinib and Bevacizumab in Stage IIIB and IV Bronchioloalveolar Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial of erlotinib plus bevacizumab in stage IIIB/IV bronchioloalveolar carcinoma (lung cancer) has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Bevacizumab (bevacizumab)
  • ERLOTINIB (Erlotinib)

Snippet

Sponsor: SWOG Cancer Research Network | Conditions: Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2016-12-22